FDA Sends Complete Response Letter To AstraZeneca PLC (ADR) (AZN) Following Rejection Of Hyperkalemia Drug
AstraZeneca PLC (ADR) (NYSE:AZN) has acknowledged the receipt of the Complete Response Letter (CRL) from the U.S.
Posts Tagged ‘Is AZN A Good Stock To Buy Right Now?’
AstraZeneca PLC (ADR) (AZN) In Respiratory Drug Deal With Circassia Pharmaceuticals
In an effort to enhance collaboration with Circassia Pharmaceuticals, AstraZeneca PLC (ADR) (NYSE:AZN) has acquired an equity stake valued at $50 million in the respiratory biopharmaceutical...
AstraZeneca PLC (ADR) (AZN)’s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO)
Lynparza, an ovarian cancer treatment developed by AstraZeneca PLC (ADR) (NYSE:AZN) has demonstrated its ability to slow down disease progression.
Here’s What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology Inc (CLVS)
It’s been a big week for PARP inhibitors.
AstraZeneca PLC (ADR) (AZN) Rejected Drugs To Be Reconsidered
AstraZeneca plc (ADR) (NYSE:AZN) is reconsidering some of its rejected drugs, as they could possess potential in curing a disease they were not initially meant to treat.
China MediTech And AstraZeneca PLC (ADR) (AZN) To Present Savolitinib Phase II Results At The Genitourinary Cancers Symposium 2017
Hutchison China MediTech Limited and AstraZeneca plc (ADR) (NYSE:AZN) are to present data from their phase II clinical trials of Savolitinib, at the upcoming 2017 Genitourinary...
Clovis Oncology Inc (CLVS)’s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO)
Trials of rival drugs from AstraZeneca PLC (ADR) (NYSE:AZN) and TESARO Inc (NASDAQ:TSRO) will determine the adoption of the PARP inhibitor, Rubraca from Clovis Oncology Inc (NASDAQ...
AstraZeneca PLC (ADR) (AZN) Wins A Six Months Paediatric Exclusivity Approval Of Its Symbicort
The US Food and Drug Administration (FDA) has confirmed that Symbicort (budesonide/formoterol) Inhalation Aerosol is worth being granted paediatric exclusivity.
AstraZeneca PLC (ADR) (AZN) Planning Tagrisso Label Expansion To Shore Up Earnings
AstraZeneca plc (ADR) (NYSE:AZN) share price could receive a major boost on the company pursuing a label expansion for its blockbuster Tagrisso.
AstraZeneca plc (ADR) (AZN) CEO Claims The Drug Approval Process Of NHS Is Counterproductive
AstraZeneca plc (ADR) (NYSE:AZN)’s chief executive officer has said that the long negotiation process that the NHS undertakes with drugmakers before approving medications is...
AstraZeneca PLC (ADR) (AZN) Cuts Jobs, Signs New Collaboration With Eli Lilly And Co (LLY)
“By diligently prioritizing, we will continue to successfully launch and commercialize new medicines, meet the needs of our customers and patients, and ultimately help AstraZeneca...
Can AstraZeneca Plc (AZN) Lung Cancer Pill Take Over Chemo Treatment?
Tagrisso, a lung cancer med from AstraZeneca plc (ADR) (NYSE:AZN) is already in early approval based on mid-stage studies, which demonstrates the possibility of it replacing the...
AstraZeneca PLC (ADR) (AZN) Relocating Jobs At U.K. Division
AstraZeneca plc (ADR) (NYSE:AZN) plans to cut some back office jobs in the U.K. as the company works toward cost-cutting and operation consolidation.
AstraZeneca PLC (ADR) (AZN), Ranbaxy Laboratories Limited (ADR) (RBXLY) Wins Over Illegal Deal Case
The 1st US Circuit Court of Appeals has recently ruled in favor of AstraZeneca plc (ADR) (NYSE:AZN) and Ranbaxy Laboratories Limited (ADR) (OTCMKTS:RBXLY) on a long-lasting class...
AstraZeneca PLC (ADR) (AZN) Retreats On Some Durvalumab Plans
AstraZeneca PLC (ADR) (NYSE:AZN) will no longer seek early regulatory review of its drug candidate durvalumab in patients with head and neck cancers.
AstraZeneca PLC (ADR) (AZN) Unveils Positive SOLO-2 Data
AstraZeneca plc (ADR) (NYSE:AZN) has recently released encouraging data from SOLO-2, a phase 3 clinical trial evaluating the efficacy of Lynparza (olaparib) as a monotherapy for...
AstraZeneca Plc (ADR) (AZN) Offloads Two Diabetes Drugs to Focus on Core Therapeutic Areas
AstraZeneca Plc (ADR) (NYSE:AZN) has once again reiterated its intention to focus on core therapeutic areas with the signing of a new commercialization agreement with a subsidiary...
